Tuesday, November 19, 2002 12:59:14 PM
IBCI Receives Patent Approval for Treatment of Foods and Food Containers:IBCI Moves to Northeast Distribution Program After Completing Agreements in TheSoutheast
ATLANTA, Nov 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL) announces today that it has recently received from the U.S. Patent Office an approval extending IBCI's antimicrobial, securing the rights to a broader protection of its proprietary technology. This new patent approval helps IBCI to move into the food market upon completion of FDA approval, bringing achievement to our on-going plans for international growth. Deirdre Baker, IBCI's General Manager stated, "This new Patent approval contributes a great deal to our competitive advantage, creates new barriers to entry for our competition to participate in the antimicrobial and antibacterial industries, and further enhances and protects IBCI's intellectual property portfolio." IBCI continues to expand its distribution program, working with specialty distributors in the Northeast and Midwest. In addition IBCI will be in a plant shutdown and mandatory vacation time during the week of Thanksgiving.
About BioShield Technologies, Inc./International BioChemical Industries, Inc.:
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria, including HIV, on contact and can remain active for extended time periods. To date BioShield has received three US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.
Further information on IBCI and its line of products can be found by visiting the firm's web site at www.bioshield.com , or by calling Deirdre Baker at 1-770-925-3653.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
Make Your Opinion Count - Click Here
tbutton.prnewswire.com/prn/11690X36385639
SOURCE International BioChemical Industries, Inc.
CONTACT: Deirdre Baker of International BioChemical Industries, Inc.,
+1-770-925-3653
The best weapon against "fear" is "facts"!!
ATLANTA, Nov 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL) announces today that it has recently received from the U.S. Patent Office an approval extending IBCI's antimicrobial, securing the rights to a broader protection of its proprietary technology. This new patent approval helps IBCI to move into the food market upon completion of FDA approval, bringing achievement to our on-going plans for international growth. Deirdre Baker, IBCI's General Manager stated, "This new Patent approval contributes a great deal to our competitive advantage, creates new barriers to entry for our competition to participate in the antimicrobial and antibacterial industries, and further enhances and protects IBCI's intellectual property portfolio." IBCI continues to expand its distribution program, working with specialty distributors in the Northeast and Midwest. In addition IBCI will be in a plant shutdown and mandatory vacation time during the week of Thanksgiving.
About BioShield Technologies, Inc./International BioChemical Industries, Inc.:
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria, including HIV, on contact and can remain active for extended time periods. To date BioShield has received three US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.
Further information on IBCI and its line of products can be found by visiting the firm's web site at www.bioshield.com , or by calling Deirdre Baker at 1-770-925-3653.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
Make Your Opinion Count - Click Here
tbutton.prnewswire.com/prn/11690X36385639
SOURCE International BioChemical Industries, Inc.
CONTACT: Deirdre Baker of International BioChemical Industries, Inc.,
+1-770-925-3653
The best weapon against "fear" is "facts"!!
The best weapon against "fear" is "facts"!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
